We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

15 hedge funds and large institutions have $27.5M invested in Akari Therapeutics in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

12% less funds holding

Funds holding: 17 → 15 (-2)

18% less capital invested

Capital invested by funds: $33.7M → $27.5M (-$6.15M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
15
Holders Change
-2
Holders Change %
-11.76%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$6.46K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$197K
2
RCM
RA Capital Management
Massachusetts
-$103K
3
QF
QVT Financial
New York
-$45.2K
4
ACH
ArrowMark Colorado Holdings
Colorado
-$7K
5
TRCT
Tower Research Capital (TRC)
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$8.1M – – –
VC
2
Vivo Capital
California
$3.72M – – –
BBA
3
Baker Bros. Advisors
New York
$3.5M – – –
NMC
4
NEA Management Company
Maryland
$3.18M – – –
VMI
5
VHCP Management II
New York
$2.6M – – –
QF
6
QVT Financial
New York
$1.45M -$45.2K -7 -2%
FCMI
7
Foresite Capital Management III
California
$1.39M – – –
VM
8
VHCP Management
New York
$1.11M – – –
BC
9
Boxer Capital
California
$985K – – –
RCM
10
RA Capital Management
Massachusetts
$714K -$103K -16 -11%
GTC
11
Ghost Tree Capital
New York
$328K – – –
Deutsche Bank
12
Deutsche Bank
Germany
$164K – – –
UBS Group
13
UBS Group
Switzerland
$152K -$6.46K -1 -4%
SM
14
Sabby Management
Florida
$120K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$4K +$6.46K +1 New
Morgan Stanley
16
Morgan Stanley
New York
$2K – – –
ACP
17
Acuta Capital Partners
California
– -$197K -29 Closed
ACH
18
ArrowMark Colorado Holdings
Colorado
– -$7K -1 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$7K -1 Closed

AKTX Hedge Fund Activity: Q4 2016 in Review

15 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2016, worth a combined $27.5M — down 18% from $33.7M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AKTX and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 0 added.

The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $6.46K. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $197K sold.

  • 15 institutional investors held Akari Therapeutics (AKTX) as of Q4 2016, down from 17 in Q3 2016.
  • Funds reported $27.5M of Akari Therapeutics stock for Q4 2016, down 18% quarter-over-quarter.
  • 1 fund opened new Akari Therapeutics positions in Q4 2016 and 3 closed out, a net change of -2 holders.
  • The largest Akari Therapeutics buyer in Q4 2016 was Royal Bank of Canada, an estimated $6.46K added.
  • The largest Akari Therapeutics seller in Q4 2016 was Acuta Capital Partners, an estimated $197K sold.

Based on aggregated 13F filings for Q4 2016.